Selective proapoptotic activity of polyphenols from red wine on teratocarcinoma cell, a model of cancer stem-like

Tanveer Sharif1, Cyril Auger, Christian Bronner

  • 1UMR 7213 CNRS, Laboratoire de Biophotonique et Pharmacologie, Université de Strasbourg, B.P. 60024, Illkirch, 67401, France.

Investigational New Drugs
|November 28, 2009
PubMed

Insights

Red wine polyphenols (RWPs) show anticancer potential by inhibiting cancer stem cell proliferation and inducing apoptosis. This study highlights RWPs

Area of Science:

  • * Cancer Biology
  • * Pharmacology
  • * Molecular Oncology

Background:

  • * Cancer stem cells (CSCs) drive tumor initiation and metastasis, making them key therapeutic targets.
  • * Lack of reliable CSC models hinders the development of novel anticancer therapies.
  • * Teratocarcinoma cells, as malignant totipotent stem cells, serve as a valuable model for CSC research.

Purpose of the Study:

  • * To evaluate the chemopreventive activity of red wine polyphenols (RWPs) on cancer stem cells.
  • * To elucidate the cellular and molecular mechanisms underlying RWPs' effects.
  • * To validate embryonal carcinoma (EC) cell lines as a model for CSC drug screening.

Main Methods:

  • * Investigated RWPs' effects on the P19 embryonal carcinoma (EC) cell line, a CSC model.
  • * Utilized NIH/3T3 fibroblasts as a normal cell counterpart for comparative analysis.
  • * Analyzed cell proliferation, cell cycle progression (G1 arrest), apoptosis, p53 gene expression, and caspase-3 activation.

Main Results:

  • * RWPs selectively inhibited P19 EC cell proliferation in a dose-dependent manner.
  • * RWPs induced G1 cell cycle arrest in P19 EC cells.
  • * RWPs triggered apoptosis in P19 EC cells, associated with p53 upregulation and caspase-3 activation.

Conclusions:

  • * RWPs exhibit chemopreventive activity against tumor initiation and development by inhibiting CSC proliferation and inducing apoptosis.
  • * The observed effects are mediated through a p53-dependent apoptotic pathway in teratocarcinoma cells.
  • * EC cell lines are suitable models for studying CSC responses to potential anticancer agents.

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...